Clinical Trial Update: Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating the safety and efficacy of REP 2139 (REP 9AC') in patients with chronic hepatitis B infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• REP 2139 (REP 9AC') (REP 9AC)

Snippet

Sponsor: Replicor Inc. | Conditions: Hepatitis B, Chronic | Phase 1, Phase 2 | Status: COMPLETED